FDA Releases Draft Guidance for MRD and CR as Endpoints to Support Accelerated Approval for Myeloma Drugs (https://www.myeloma.org/news-events/multiple-myeloma-news/fda-draft-guidance-mrd-cr-endpoints-accelerated-approval-myeloma-drugs)